期刊文献+

依那普利、厄贝沙坦及血管紧张素-(1—7)对快速心房起搏犬肾素-血管紧张素系统的影响 被引量:1

Effects of enalapril, irbesartan and angiotensin-( 1-7 ) on the expression of renin angiotensin system in a canine model of rapid atrial pacing
原文传递
导出
摘要 目的观察快速心房起搏模型犬血管紧张素转换酶2(ACE2)和血管紧张素III型受体(ATlR)mRNA表达的变化,以及应用依那普利、厄贝沙坦及血管紧张素(Ang)-(1-7)对其影响。方法健康成年杂种犬30只,分为5组:假手术组(S组),心房起搏对照组(C组),心房起搏+依那普利组(EN组),心房起搏+厄贝沙坦组(IB组),心房起搏+血管紧张素-(1-7)组(A组),每组6只。S组植入起搏器,但不行起搏刺激及药物干预。C组植入起搏器并起搏,但无药物干预。EN组及IB组分别于起搏开始前3d开始给予口服依那普利2mg·kg^-1·d^-1或厄贝沙坦60mg·kg^-1·d^-1。A组给予Ang-(1-7)6μg·kg^-1·h^-1持续静脉泵人。各组犬经500次/min快速心房起搏2周后,采集右心房肌标本,逆转录聚合酶链式反应(RT—PCR)检测心房肌组织中ACE2和ATlRmRNA表达。结果心房起搏组较假手术组ACE2表达降低,ATlR表达明显升高,应用依那普利、厄贝沙坦和Ang-(1-7)可使ACE2表达增加和ATIR水平下调。结论快速心房起搏2周可诱发心脏局部肾素-血管紧张素(RAS)系统的活化,依那普利、厄贝沙坦和Ang-(1-7)可抑制起搏后的RAS系统激活,降低心房颤动的易感性。Ang-(1-7)的心脏保护作用可能通过下调ATIR和上调ACE2来介导。 Objective To investigate the mRNA expression of angiotensin converting enzyme 2 (ACE2) and angiotensin II type 1 receptor( AT1 R) in a canine model of rapid atrial pacing and the effects of enalapril, irbesmtan and angiotensin-( 1-7 ) on ACE2 and ATI R expression. Methods Thirty mongrel dogs were assigned to the sham-operated group ( S, n = 6), pacing-control group ( C, n = 6 ), pacing and enalapriltreated group( EN, n = 6 ) , pacing and irbesartan-treated group ( IB, n = 6 ) or pacing and Ang-( 1-7 ) -treated group(A, n = 6). The rapid atrial pacing at 500 beats per minute was maintained for 2 weeks except sham group. The dogs in the EN, IB and A groups respectively received enalapril (2 mg· kg^-1· d^-1 ), irbesartan ( 60 mg· kg ^- 1· d^ - 1 ) orally or Ang- ( 1-7 ) ( 6 μg · kg ^- 1 . h^ - 1 ) intravenously during the pacing period. RTPCR was applied to assess the mRNA expression of ACE2 and AT1R in right atrial tissue. Result In the pacing-control group, ACE2 mRNA expression was declined and AT1R expression was markedly elevated than sham group. Enalapril, irbesartan or angiotensin-( 1-7 ) treatement caused increased ACE2 mRNA expression and decreased AT1R expression in comparison with the pacing-control group. Conclusion Chronic rapid atrial pacing leads to renin angiotensin system activation which is contributed to the atrial fibrillation. Enalapril,irbesartan and angotensin- ( 1-7 ) can suppress the activation of RAS, thereby reducing the atrial fibrillation vulnerability. The cardiac protection of angiotcnsin-( 1-7 ) probably is mediated by the downregulation of AT1R and increased ACE2 expression.
出处 《中华心律失常学杂志》 2010年第4期283-286,共4页 Chinese Journal of Cardiac Arrhythmias
基金 基金项目:国家自然科学基金(30770863)
关键词 血管紧张素-(1-7) 心房起搏 肾素-血管紧张素系统 Angiotensin- ( 1-7 ) Atrial pacing Renin angiotensin system
  • 相关文献

参考文献11

  • 1Allessie M,Ausma J,Schotten U.Electrical,contractile and structural remodeling during atrial fibrillation.Cardiovase Res,2002,54:230-246.
  • 2Ehrlich JR,Hohnloser S,Nattel S.Role of angiotensin system and effects of its inhibition in atrial fibrillation:clinical and experimental evidence.Eur Heart J,2006,27:512-518.
  • 3Goette A,Staack T,Rocken C,et al.Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation.J Am Coll Cardiol,2000,35:1669-1677.
  • 4Li D,Shinagawa K,Pang L,et al.Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.Circulation,2001,104:2608-2614.
  • 5Boldt A,Wetzel U,Garbade J,et al.Expression of angiotensin Ⅱ receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease.J Am Coll Cardiol,2003,42:1785-1792.
  • 6Goette A,Arndt M,Rocken C,et al.Regulation of angiotensin Ⅱ receptor subtypes during atrial fibrillation in humans.Circulation,2000,101:2678-2681.
  • 7Tipnis SR,Hooper NM,Hyde R,et al.A human homolog of angiotensin-converting enzyme.Cloning and functional expression as a captoprilin sensitive carboxypeptidase.J Biol Chem,2000,275:33238-33243.
  • 8Donoghue M,Hsieh F,Baronas E,et al.A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1 -9.Circ Res,2000,87:E1 -E9.
  • 9Tallant EA,Ferrario CM,Gallagher PE.Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the Mas receptor.Am.J Physiol Heart Circ Physiol,2005,289:H1560-H1566.
  • 10Iwata M,Cowling RT,Gurantz D,et al.Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects.Am J Physiol Heart Circ Physiol,2005,289:H2356-H2363.

同被引文献19

  • 1Alonso A, Bengtson LG. A rising tide: the global epidemic of atrial fibrillation[J]. Circulation, 2014, 129 ( 8 ) 829-830. I)I: 10. 1161/ CIRCULATIONAHA. 113. 007482.
  • 2Li TJ, Zang WD, Chen YL, et al. Renin-angiotensin system inhibitors for prevention of recurrent atrial fibrillation: a meta-analysis[J]. Int J Clin Pract, 2013, 67(6):536-543. DOI: 10. 1111/ijcp. 12063. Dalla.
  • 3VM,Simioni N, Masiero A. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity[J]. Minerva Endocrinol, 2009, 34(4) : 333-338.
  • 4Zhao Z, Wang X, Li J, et al. Protective effects of aliskiren on atrial ionic remodeling in a canine model of rapid atrial pacing[J]. Cardiovasc Drugs Ther, 2014, 28 (2) : 137-143. DOI: 10. lO07/s10557-O14- 6509-x.
  • 5Nakashima H, Kumagai K. Reverse-remodeling effects of angiotensin U type 1 receptor blocker in a canine atrial fibrillation model [J]. Circ J, 2007, 71 (12) .. 1977-1982.
  • 6Goette A, Staack T, Rocken C, et al. Increased expression of extracellular sign at eregulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation[J]. J Am Coll Cardiol, 2000, 35( 6): 1669-1977.
  • 7Kalus JS, Coleman CI, White CM. The impact of suppressing the renin-angiotensin system on atrial fibrillation[J]. Clin Pharmacol, 2006, 46(1): 21-28.
  • 8Liu E, Xu Z, Li J, et al. Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachyeardia-induced ionic remodeling[J]. Int J Cardiol, 2011, 146(3): 364-370. DOI: 10. 1016/i. iicard. 2009.07. 015.
  • 9Yamamoto E, Kataoka K, Dong YF, ct al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitricoxide synthase-deficient mice [ J ] Hypertension, 2009, 54 ( 3 ) : 633-638. DOI: 10. 1161/HYPERTENSIONAHA. 109, 133884.
  • 10Dong YF, Liu L, Lai ZF, et al. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice[J]. J Hypertens, 2010, 28(7): 1554-1565. DOI: 10. 1097/HJH. 0b013e328338bb11.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部